Condition (MeSH)
Exanthema
ClinicalTrials.gov lists 62 trials for Exanthema or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
62 of the 62 trials are tagged with Exanthema itself; the rest are tagged with a narrower condition beneath it.
When did Exanthema trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 2 |
| 2017 | 3 |
| 2016 | 3 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Exanthema trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 17 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Phase 4 | 4 |
| Not applicable | 11 |
| Observational | 19 |
How many Exanthema trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 31 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Exanthema trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Amgen | 2 |
| Merz North America, Inc. | 2 |
| Novartis Pharmaceuticals | 2 |
| Allergan | 1 |
| Aucta Pharmaceuticals, Inc | 1 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Exanthema? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Prednisone | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| MSRD-100 | 2 |
| ACZONE (dapsone) Gel, 5% | 1 |
| Application of Onco-Neutre cream | 1 |
| Oral Antibiotics | 1 |
| Topical Dapsone 5% Gel | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Exanthema trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| DEHYDRATION | 12 | 1 |
| DIARRHOEA | 10 | 1 |
| VOMITING | 7 | 1 |
| ABDOMINAL PAIN | 5 | 1 |
| NAUSEA | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Exanthema? (214)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies. | The Journal of clinical investigation | 2024 | Yes |
| Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. | Cancer | 2024 | Yes |
| Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. | Cancer research communications | 2024 | Yes |
| Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans. | Science translational medicine | 2024 | Yes |
| Impact of Eruptive vs Noneruptive Calcified Nodule Morphology on Acute and Long-Term Outcomes After Stenting. | JACC. Cardiovascular interventions | 2023 | Yes |
Showing 5 of 214 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.